These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 29986989)

  • 1. Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.
    Shahreyar M; Salem SA; Nayyar M; George LK; Garg N; Koshy SKG
    J Am Board Fam Med; 2018; 31(4):628-634. PubMed ID: 29986989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
    Noel ZR; Beavers CJ
    Am J Med; 2017 Feb; 130(2):229.e1-229.e4. PubMed ID: 27751895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 inhibition - a novel mechanism to treat lipid disorders?
    Banach M; Rizzo M; Obradovic M; Montalto G; Rysz J; Mikhailidis DP; Isenovic ER
    Curr Pharm Des; 2013; 19(21):3869-77. PubMed ID: 23286435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.
    Lambert G; Thedrez A; Croyal M; Ramin-Mangata S; Couret D; Diotel N; Nobécourt-Dupuy E; Krempf M; LeBail JC; Poirier B; Blankenstein J; Villard EF; Guillot E
    Clin Sci (Lond); 2017 Feb; 131(4):261-268. PubMed ID: 28108631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
    Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
    Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
    Stein EA
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world use of PCSK9 inhibitors: A single-center experience.
    Sarsam S; Berry A; Degheim G; Singh R; Zughaib M
    J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihyperlipidemic therapies targeting PCSK9.
    Weinreich M; Frishman WH
    Cardiol Rev; 2014; 22(3):140-6. PubMed ID: 24407047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Dijk W; Cariou B
    Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():39-51. PubMed ID: 31002456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy.
    Milionis H; Liamis G; Elisaf M
    Expert Opin Biol Ther; 2015 Feb; 15(2):287-98. PubMed ID: 25491324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive LDL-cholesterol lowering therapy and neurocognitive function.
    Banach M; Rizzo M; Nikolic D; Howard G; Howard V; Mikhailidis D
    Pharmacol Ther; 2017 Feb; 170():181-191. PubMed ID: 27865998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
    Lipinski MJ; Benedetto U; Escarcega RO; Biondi-Zoccai G; Lhermusier T; Baker NC; Torguson R; Brewer HB; Waksman R
    Eur Heart J; 2016 Feb; 37(6):536-45. PubMed ID: 26578202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD; Kei A; Rizos CV; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):3-12. PubMed ID: 28826253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.